Astellas Pharma and CoMentis have entered into an exclusive worldwide collaboration agreement to develop and commercialize products from CoMentis’ beta-secretase inhibitor program, including its lead candidate CTS-21166, an orally bioavailable, small-molecule beta-secretase inhibitor being developed as a disease-modifying treatment for Alzheimer’s disease. The agreement also includes a research collaboration to develop additional beta-secretase inhibitors.     CoMentis will receiv...